147 related articles for article (PubMed ID: 6403413)
1. A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer.
Edwards CL; Herson J; Gershenson DM; Copeland LJ; Wharton JT
Gynecol Oncol; 1983 Apr; 15(2):261-77. PubMed ID: 6403413
[TBL] [Abstract][Full Text] [Related]
2. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma.
Omura GA; Morrow CP; Blessing JA; Miller A; Buchsbaum HJ; Homesley HD; Leone L
Cancer; 1983 Mar; 51(5):783-9. PubMed ID: 6401594
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
4. Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens.
Vogl SE; Pagano M; Kaplan BH; Greenwald E; Arseneau J; Bennett B
Cancer; 1983 Jun; 51(11):2024-30. PubMed ID: 6404547
[TBL] [Abstract][Full Text] [Related]
5. cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma.
Carmo-Pereira J; Costa FO; Henriques E
Cancer Chemother Pharmacol; 1983; 10(2):100-3. PubMed ID: 6403254
[TBL] [Abstract][Full Text] [Related]
6. Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.
Razis DV; Poulakou E; Petounis A; Papadimitriou G; Kosmides P; Delides G
Oncology; 1982; 39(4):205-8. PubMed ID: 6806735
[TBL] [Abstract][Full Text] [Related]
7. Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial.
Sessa C; Bolis G; Colombo N; D'Incalci M; Mermillod B; Valente I; Mangioni C
Cancer Chemother Pharmacol; 1985; 14(3):222-8. PubMed ID: 3922639
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer.
Bruckner HW; Cohen CJ; Goldberg JD; Kabakow B; Wallach RC; Deppe G; Reisman AZ; Gusberg SB; Holland JF
Am J Obstet Gynecol; 1983 Mar; 145(6):653-8. PubMed ID: 6402934
[TBL] [Abstract][Full Text] [Related]
9. Hexamethylmelamine, cyclophosphamide, adriamycin, cis-platinum chemotherapy as initial and second-line treatment of advanced ovarian carcinoma.
Richman CM; Podczaski E; Weiser PA; Herbst AL
Oncology; 1986; 43(1):12-7. PubMed ID: 3079898
[TBL] [Abstract][Full Text] [Related]
10. Single-agent cis-platinum therapy for advanced ovarian cancer.
Gershenson DM; Wharton JT; Herson J; Edwards CL; Rutledge FN
Obstet Gynecol; 1981 Oct; 58(4):487-96. PubMed ID: 7024883
[TBL] [Abstract][Full Text] [Related]
11. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
Young RC; Chabner BA; Hubbard SP; Fisher RI; Bender RA; Anderson T; Simon RM; Canellos GP; DeVita VT
N Engl J Med; 1978 Dec; 299(23):1261-6. PubMed ID: 101843
[TBL] [Abstract][Full Text] [Related]
12. The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II).
Vogl SE; Berenzweig M; Kaplan BH; Moukhtar M; Bulkin W
Cancer Treat Rep; 1979 Feb; 63(2):311-7. PubMed ID: 109202
[TBL] [Abstract][Full Text] [Related]
13. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results.
Sessa C; Colombo N; Bolis G; Marsoni S; Mangioni C
Cancer Treat Rev; 1991 Mar; 18 Suppl A():37-46. PubMed ID: 1904308
[No Abstract] [Full Text] [Related]
15. Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma.
Kane R; Harvey H; Andrews T; Bernath A; Curry S; Dixon R; Gottlieb R; Kukrika M; Lipton A; Mortel R; Ricci J; White D
Cancer Treat Rep; 1979 Feb; 63(2):307-9. PubMed ID: 109201
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide.
Schwartz PE; Lawrence R; Katz M
Cancer Treat Rep; 1981; 65(1-2):137-41. PubMed ID: 6261948
[TBL] [Abstract][Full Text] [Related]
17. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
Greco FA; Johnson DH; Hainsworth JD
Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
[TBL] [Abstract][Full Text] [Related]
18. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Kooyman CD; van Lindert AC; Hamerlynck JV; van Lent M; van Houwelingen JC
Lancet; 1984 Sep; 2(8403):594-600. PubMed ID: 6147640
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy of advanced ovarian cancer with hexamethylmelamine, cis-Platinum, and doxorubicin after failure of prior therapy.
Vogl SE; Pagano M; Kaplan BH; Einhorn N; Arseneau J; Moukhtar M; Greenwald E
Obstet Gynecol; 1980 Nov; 56(5):635-40. PubMed ID: 6776457
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer--ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group.
Tropé C; Andersson H; Björkholm E; Frankendal B; Himmelman A; Högberg T; Horvath G; Petterson B; Persson H; Ryberg M; Simonsen E; Sorbe B; Stendahl U; Westholm B
Acta Oncol; 1996; 35 Suppl 8():109-18. PubMed ID: 9073056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]